Screener
ImmunityBio, Inc. IBRX Pre-Tax Income
Pre-Tax Income at other companies
Segments
By segment
Other financials
Where this comes from
Reported directly by ImmunityBio, Inc. in its filing.
Tagged under the XBRL concept us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest.
The source filing: ImmunityBio, Inc.’s 10-Q, filed May 7, 2026.
- Filed
- May 7, 2026, 7:37 AM EDT
- Fiscal quarter
- Q1 FY2026
- Calendar quarter
- Q1 2026
- Accession
- 0001326110-26-000059
| Line item | Three Months Ended March 31, 2026 | Three Months Ended March 31, 2025 |
|---|---|---|
| Interest expense | (34) | (18) |
| Other expense, net | (5,917) | (41) |
| Total other expense, net | (562,997) | (65,471) |
| Loss before income taxes and noncontrolling interest | (632,788) | (129,900) |
| Income tax (expense) benefit | (9) | 234 |
| Net loss | (632,797) | (129,666) |
| Net loss attributable to noncontrolling interests, net of tax | (15) | (20) |
| Net loss attributable to ImmunityBio common stockholders | $(632,782) | $(129,646) |
ITEM 1. FINANCIAL STATEMENTS.
FAQ
- What is ImmunityBio, Inc.'s pre-tax income?
- ImmunityBio, Inc. (IBRX) reported pre-tax income of -$632.79M in Q1 2026.
- How has ImmunityBio, Inc.'s pre-tax income changed year-over-year?
- ImmunityBio, Inc.'s pre-tax income decreased by 387.1% year-over-year, from -$129.9M to -$632.79M.
- What is the long-term trend for ImmunityBio, Inc.'s pre-tax income?
- Over 4 years (2021 to 2025), ImmunityBio, Inc.'s pre-tax income has grown at a 0.1% compound annual growth rate (CAGR), from -$349.84M to -$351.61M.
- What does pre-tax income mean?
- Total income from all sources — operating income plus non-operating items like interest income, investment gains, and other income — before the provision for income taxes.
Ask your AI about ImmunityBio, Inc.'s pre-tax income.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude